



RNS Press Release

For release: 21 March 2016

**Award of Funding for Next Stage of US Department of Defense Programme
To Develop Genedrive® Biohazard Identification Tests**

Epistem Holdings Plc (LSE: EHP), the molecular diagnostics, personalised medicine and biotechnology company, announces today that the US Department of Defense has awarded \$2.9m in funding for the next phase of Epistem's programme to develop a handheld Genedrive® test for biohazard identification.

In August 2015, Epistem announced the first \$2.4m phase of the \$7.8m programme with the US Department of Defense for the development and manufacture of Genedrive® as a biohazard identification system. The second phase announced today was triggered by successful progress to date and is expected to be largely undertaken during the financial year 2016/17.

David Budd, CEO of Epistem, commented "Today's announcement is a recognition of our team's expertise in developing new assays and marks a further important validation of Genedrive®'s potential as a highly versatile molecular diagnostic system which can be used outside a central lab setting. The US Department of Defense programme funding increases our overall development capability and our ability to develop Genedrive® to realise its full potential."

-Ends-

For further details please contact:

Epistem Holdings Plc

David Budd: CEO

+44 (0)161 606 7258

John Rylands: Finance Director

Peel Hunt LLP

James Steel

+44 (0)207 418 8900

Tom Burt

Oliver Jackson

Consilium Strategic Communications

Chris Gardner / Laura Thornton

+44 (0)203 709 5700

epistem@consilium-comms.com